Page 332 - 2021_02-Haematologica-web

646
Case Reports
11. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004; 104(3):735-743.
12. Locatelli F, Jordan MB, Allen CE, et al. Safety and efficacy of ema- palumab in pediatric patients with primary hemophagocytic lym- phohistiocytosis. Blood. 2018;132(Suppl 1):LBA-6.
13. De Benedetti F, Brogan P, Grom P, et al. Emapalumab, an interferon gamma (IFNγ) blocking monoclonal antibody, in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA). Ann Rheum Dis. 2019;78 (Suppl
2):178.
14. Lounder DT, Bin Q, de Min C, Jordan MB. Treatment of refractory
hemophagocytic lymphohistiocytosis with emapalumab despite
severe concurrent infections. Blood Adv. 2019;3(1):47-50.
15. Prencipe G, Caiello I, Pascarella A, et al. Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol.
2018;141(4):1439-1449.
16. Buatois V, Chatel L, Cons L, et al. Use of a mouse model to identify
a blood biomarker for IFNγ activity in pediatric secondary hemo- phagocytic lymphohistiocytosis. Transl Res. 2017;180:37-52.
haematologica | 2021; 106(2)